Aqur Biosciences

Executive Summary

Aqur Biosciences is a privately held, early-stage biotechnology company headquartered in Westlake Village, California, dedicated to revolutionizing cardiovascular health through innovative small molecule therapeutics. Founded in 2019, the company focuses on developing breakthrough treatments for cardiovascular diseases, aiming to address significant unmet medical needs. Although specific pipeline details and financial data are not publicly disclosed, Aqur Biosciences emphasizes cutting-edge science and medical innovation. The company operates in a highly competitive therapeutic area, but its differentiated approach and strategic positioning in Southern California's biotech hub provide a foundation for potential growth. As a private entity with no disclosed funding or valuation, Aqur remains in a preclinical or early clinical stage, requiring further validation through data readouts and regulatory milestones. The company's success hinges on advancing its lead programs through preclinical and clinical development, securing partnerships or financing, and ultimately demonstrating efficacy and safety in human trials.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Preclinical Data Release40% success
• H1 2027Series A Financing Round Announcement50% success
• H2 2027IND Filing for Lead Asset30% success